Ocular Therapeutix, Inc.

Ocular Hypertension: Over 60 Companies Advance Clinical Trial Pipeline

4 months ago

• The ocular hypertension market is expanding due to increased prevalence of conditions affecting aqueous humor outflow, leading to elevated intraocular pressure (IOP). • Advancements like sustained-release implants and micro-dosing technologies are enhancing patient compliance and improving outcomes in ocular hypertension treatment. • Enhanced imaging techniques, such as optical coherence tomography (OCT), facilitate early diagnosis and intervention, contributing to the growth of the ocular hypertension market. • Over 60 companies are actively developing more than 70 pipeline drugs for ocular hypertension, signaling robust innovation and future growth potential in the domain.

Ocular Therapeutix Advances AXPAXLI for Wet AMD and Plans NPDR Clinical Trial

4 months ago

• Ocular Therapeutix's SOL-R trial for AXPAXLI in wet AMD has enrolled 311 subjects, showing significant progress in the registrational program. • The SOL-1 trial, another registrational study for AXPAXLI in wet AMD, completed randomization in December 2024, with topline data expected in Q4 2025. • Ocular Therapeutix plans to seek FDA feedback in H1 2025 on the clinical trial design for AXPAXLI in non-proliferative diabetic retinopathy (NPDR). • Phase 1 HELIOS trial results showed a single AXPAXLI injection potentially reduces vision-threatening complications in NPDR patients.

Ocular Therapeutix to Present AXPAXLI Update at J.P. Morgan Healthcare Conference

4 months ago

• Ocular Therapeutix will present its 2025 strategic outlook at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. • An update on the enrollment status of the SOL-R trial, evaluating AXPAXLI for wet AMD, will be provided during the presentation. • The presentation will also cover future opportunities for AXPAXLI and a general corporate overview of Ocular Therapeutix. • The live presentation will be accessible via the Ocular Therapeutix website in the Investor Relations section.

Ocular Therapeutix Accelerates Axpaxli Wet AMD Trial, Anticipates Topline Data in Q4 2025

7 months ago

• Ocular Therapeutix accelerates the SOL-1 Phase 3 trial for Axpaxli in wet AMD, expecting full enrollment by the end of 2024. • Topline data from the SOL-1 superiority study are now anticipated in the fourth quarter of 2025, ahead of previous estimates. • The ongoing Phase 3 program, including SOL-1 and SOL-R trials, aims to support regulatory filing for Axpaxli in treating wet AMD. • SOL-1 has over 100 active clinical trial sites, reflecting strong investigator and patient interest in Axpaxli's potential.

Dextenza Insert Shows Strong Efficacy in Allergic Conjunctivitis Phase 3 Trial

8 months ago

• A Phase 3 trial of the dexamethasone intracanalicular insert (Dextenza) met its primary endpoint, significantly reducing ocular itching associated with allergic conjunctivitis. • The study demonstrated statistically significant improvements in conjunctival redness and other secondary endpoints, indicating broad relief from allergic conjunctivitis symptoms. • Dextenza showed a favorable safety profile, with no serious adverse events reported and a low incidence of treatment-related ocular adverse events. • The sustained-release insert offers a preservative-free, physician-administered alternative to traditional eye drops, potentially improving patient compliance and reducing overuse.